HOME>News & Media>LATUDA Press Room
Healthy bodies, healthy lives

On October 28, 2010, the U.S. FDA approved Sunovion's Latuda® (lurasidone HCl) tablets for the treatment of patients with schizophrenia. LATUDA is available by prescription in pharmacies across the United States and Puerto Rico. For more information please visit www.LATUDA.com.

LATUDA® Fact Sheet

Schizophrenia Fact Sheet

Schizophrenia Milestones Timeline

 

 Date  Title
02/03/11 Once-daily Latuda® (lurasidone HCl) Now Available in Pharmacies Nationwide for the Treatment of Patients with Schizophrenia
12/08/10 Latuda® (lurasidone HCl) Significantly Improves Symptoms of Schizophrenia in Fifth Positive Placebo-Controlled Study
10/28/10 FDA approves once-daily LATUDA® (lurasidone HCl) for the treatment of patients with schizophrenia

Corporate Communications
508-357-7740
84 Waterford Drive
Marlborough, MA 01752
communications@sunovion.com

Home | Who We Are | Our Products | For Our Patients | Working at Sunovion | For Healthcare Professionals | Site Map | Terms of Use | Privacy Policy | About DSP
Sunovion is a trademark of Dainippon Sumitomo Pharma Co., Ltd., Osaka, Japan. © 2012 Sunovion Pharmaceuticals Inc., Marlborough, MA 01752. All rights reserved.